Oral Lichen Planus: Common Types, Symptoms, and Triggers

Understanding Oral Lichen Planus and Oral Mucosal Anatomy

Oral lichen planus is a chronic, cell-mediated inflammatory disorder that alters the delicate epithelial lining of the oral cavity. The oral mucosa consists of stratified squamous epithelium supported by an underlying layer of vascular connective tissue known as the lamina propria. In healthy tissue, these layers maintain a resilient barrier against chemical, thermal, and microbial irritation. When lichen planus develops, immune dysregulation causes cytotoxic T-lymphocytes to target the basal keratinocytes—the foundational cells of the epithelium—leading to cellular degeneration, disruption of the basement membrane, and variable patterns of mucosal ulceration, erythema, and hyperkeratosis.

The condition primarily targets non-keratinised and specialised mucosal tissues, although no intraoral site is completely immune. The buccal mucosa (the inner lining of the cheeks) represents the most frequently affected anatomical region, typically displaying symmetrical patterns across both sides of the mouth. The dorsum and lateral borders of the tongue, the attached gingiva (the gum tissue directly adhering to the alveolar bone), and the labial mucosa of the lips are also common sites. Involvement of the attached gingiva often presents as desquamative gingivitis, where the gums appear persistently glazed, fiery red, and prone to sloughing during routine tooth brushing.

Unlike transient oral conditions such as aphthous stomatitis (canker sores) or acute traumatic ulcers, oral lichen planus runs an unpredictable, relapsing and remitting course. It is not an infectious process; it cannot be transmitted to others through saliva or physical contact. However, because of its prolonged chronicity and potential to mimic other serious mucosal disorders—including oral potentially malignant disorders and mucosal pemphigoid—precise clinical differentiation and long-term surveillance remain vital components of oral and maxillofacial care.

Pathophysiology, Autoimmunity, and Known Triggers

The precise initiating event of oral lichen planus remains the subject of extensive immunological research, but the underlying mechanism is an organ-specific, T-cell-mediated autoimmune reaction. In genetically susceptible individuals, an uncharacterised autoantigen or modified exogenous peptide is presented by major histocompatibility complex (MHC) molecules on the surface of basal keratinocytes. In response, CD8+ cytotoxic T-lymphocytes migrate into the lamina propria, initiating programmed cell death (apoptosis) within the basal epithelial layer. This cascade triggers the release of pro-inflammatory cytokines, including tumour necrosis factor-alpha and interferon-gamma, which further amplify mucosal inflammation.

A wide array of local and systemic factors can exacerbate oral lichen planus symptoms or provoke distinct lichenoid reactions. Systemic medications—notably non-steroidal anti-inflammatory drugs (NSAIDs), beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, oral hypoglycaemics, and antimalarial agents—can induce oral lichenoid drug eruptions that closely mirror idiopathic lichen planus. Contact sensitivity to dental restorative materials, particularly dental amalgam containing elemental mercury or certain composite resin monomers, can also trigger localized lichenoid mucositis directly adjacent to the existing restoration.

Psychological stress is widely recognised as a significant trigger for acute clinical flares, likely mediated through neuroendocrine pathways that influence immune tolerance. Systemic associations with hepatitis C viral infection have been well documented in specific geographic populations, warranting targeted screening when clinical suspicion arises. In regions where habitual chewing of areca nut, betel quid, paan, or gutka is prevalent, the mucosal friction and chemical toxicity of these substances significantly aggravate underlying lichenoid inflammation and complicate the clinical picture by introducing overlapping precancerous tissue changes.

Recognising Oral Lichen Planus Symptoms and Clinical Patterns

The spectrum of oral lichen planus symptoms varies remarkably between individuals, ranging from asymptomatic textural changes to debilitating intraoral pain. In milder forms, patients may notice a subtle roughness, dryness, or a lacy sensation across the inner cheeks when moving their tongue. Many individuals remain entirely unaware of these changes until a dentist identifies characteristic reticular striae during a routine oral cancer screening or dental check-up. However, when inflammatory activity intensifies, symptoms can escalate rapidly to burning sensations, continuous stinging, and marked mucosal tenderness.

For patients experiencing active, erosive, or ulcerative variants, everyday functions become challenging. The ingestion of acidic foods (such as citrus and tomatoes), spicy ingredients, salty snacks, carbonated drinks, or rough textures (such as crusty bread and nuts) often provokes acute, burning discomfort. Brushing teeth with standard, highly flavoured, or sodium lauryl sulphate (SLS)-containing toothpastes can cause intense irritation. In severe cases involving desquamative gingivitis, the gums bleed spontaneously or detach with light mechanical pressure, making essential oral hygiene painful and leading to secondary plaque accumulation and periodontal inflammation.

Symptom patterns frequently fluctuate in cycles lasting weeks or months, marked by spontaneous remissions followed by symptomatic flare-ups triggered by viral illnesses, dietary indiscretions, dental procedures, or emotional distress. It is also important to note extraoral manifestations; some patients with oral disease concurrently develop cutaneous lichen planus (violaceous, pruritic, polygonal papules on the wrists and ankles), genital mucosal lesions, scalp involvement (lichen planopilaris leading to scarring alopecia), or dystrophy of the fingernails and toenails.

Diagnostic Evaluation, Incisional Biopsy, and Differential Diagnosis

A definitive diagnosis of oral lichen planus cannot be made on visual examination alone, because its clinical presentation overlaps significantly with several other chronic mucosal disorders. The gold standard for confirming the diagnosis is an incisional tissue biopsy accompanied by histopathological analysis. The clinician selects an active, representative site—ideally an area displaying non-ulcerated, hyperkeratotic striae or the intact erythematous border adjacent to an erosion—avoiding completely ulcerated centres where the loss of surface epithelium prevents accurate structural evaluation.

Under microscopic examination, classic histopathological criteria defined by the World Health Organization must be met. These include a dense, well-demarcated band-like infiltrate of T-lymphocytes confined to the superficial lamina propria, liquefaction degeneration of the basal cell layer, Civatte bodies (apoptotic, dyskeratotic keratinocytes), and variable degrees of hyperkeratosis without cellular atypia or dysplasia. Direct immunofluorescence (DIF) testing of fresh peri-lesional tissue may be performed simultaneously to detect linear deposits of fibrinogen along the basement membrane zone, which helps exclude autoimmune blistering diseases.

Differential diagnosis is broad and clinically crucial. The clinician must distinguish oral lichen planus from oral lichenoid contact lesions, mucous membrane pemphigoid, pemphigus vulgaris, systemic or discoid lupus erythematosus, chronic ulcerative stomatitis, leukoplakia, erythroplakia, and oral squamous cell carcinoma. In individuals who use tobacco or betel quid, mucosal changes must be meticulously evaluated to rule out oral submucous fibrosis or early malignancy masquerading as inflammatory erosions.

Clinical Classifications and Morphological Subtypes

Oral lichen planus is classified into six distinct clinical subtypes, which may present individually or concurrently in the same patient. The **reticular type** is the most common and classic presentation, characterised by an interlacing network of fine, slightly raised white lines known as Wickham's striae. These striae form characteristic lace-like, annular, or circular arborising patterns, most frequently located bilaterally and symmetrically on the posterior buccal mucosa. Reticular lesions are predominantly asymptomatic and carry the lowest risk of tissue breakdown.

The **papular type** consists of small, pinhead-sized white papules scattered across the mucosa, which often coalesce over time into reticular networks. The **plaque-like type** manifests as smooth or slightly irregular, fixed white plaques that closely resemble oral leukoplakia; it is most commonly observed on the dorsum of the tongue and the inner cheeks, particularly in patients with a history of tobacco use. The **atrophic (erythematous) type** presents as diffuse, fiery red patches surrounded by fine peripheral striae, reflecting marked epithelial thinning that results in notable burning sensations.

The **erosive and ulcerative types** represent the most painful and clinically concerning forms. In these subtypes, the full thickness of the epithelium is lost, producing extensive, raw ulcerations covered by a yellowish-white fibrinous pseudomembrane surrounded by an erythematous, inflamed periphery. The rarest form, the **bullous type**, features short-lived fluid-filled vesicles or bullae that rapidly rupture to leave behind painful erosive beds. Both erosive and atrophic subtypes require active, monitored therapeutic intervention to alleviate pain and restore mucosal integrity.

Evidence-Based Medical and Topical Management Options

Because oral lichen planus is a chronic autoimmune condition with no permanent cure, evidence-based management focuses on eliminating discomfort, resolving mucosal erythema and ulceration, and maintaining long-term disease remission. Asymptomatic reticular and papular lesions generally require no active pharmacotherapy; instead, clinical practice guidelines recommend observation, optimisation of oral hygiene, and periodic monitoring. When symptomatic atrophic or erosive lesions occur, first-line medical therapy centres on high-potency topical corticosteroids.

Potential topical agents include clobetasol propionate, betamethasone valerate, fluocinonide, or triamcinolone acetonide formulated in an adhesive oral paste (such as carboxymethylcellulose paste) or administered as a compounded mouthwash. These agents suppress local T-cell infiltration and reduce cytokine-mediated tissue damage. For refractory lesions unresponsive to corticosteroids, topical calcineurin inhibitors—such as tacrolimus or pimecrolimus ointment—serve as validated second-line therapies, selectively inhibiting T-lymphocyte activation without causing mucosal atrophy.

In severe, widespread, or multisystem flares that fail to respond to topical interventions, a short course of systemic corticosteroids (such as oral prednisolone) may be prescribed to gain rapid control over mucosal destruction. Long-term systemic immunosuppressants, including azathioprine, mycophenolate mofetil, or methotrexate, are reserved for highly resistant cases managed within specialised oral medicine departments. Patients using topical or systemic steroids must be monitored for secondary oral candidiasis (fungal infection), which can aggravate mucosal pain and necessitates prompt antifungal therapy with nystatin or fluconazole.

The Diagnostic and Biopsy Appointment: Step-by-Step Experience

Attending an oral medicine or maxillofacial clinic for an initial evaluation involves a systematic, methodical consultation designed to establish an accurate diagnosis safely. The appointment begins with a comprehensive medical history, reviewing all prescription and over-the-counter medications, systemic health conditions, dermatological symptoms, and lifestyle factors. The clinician then performs an extraoral examination of the head, neck, skin, and lymph nodes, followed by a thorough intraoral assessment of all soft tissues using bright clinical illumination, gentle tissue retractors, and palpation.

If a biopsy is indicated, the procedure is carried out under local anaesthesia in the outpatient chair. The clinician injects a small volume of local anaesthetic solution—typically lidocaine with adrenaline (epinephrine)—around the periphery of the chosen site to completely numb the area while avoiding direct infiltration into the lesion to prevent tissue distortion. A small, elliptical wedge or circular punch of tissue measuring approximately 4 to 6 millimetres in length is carefully excised, encompassing both the abnormal surface epithelium and the underlying lamina propria.

Once the sample is collected, it is immediately placed in a 10% neutral buffered formalin solution for standard histopathology (and optionally in Michel's transport medium if direct immunofluorescence is planned). The surgical wound is closed with one or two fine, absorbable sutures that typically dissolve within 7 to 14 days, or left to heal by secondary intention if a small punch was used. Hemostasis is verified with gentle pressure, post-operative instructions are provided in writing, and a review appointment is scheduled to discuss the pathology findings.

Healing Expectations, Dietary Modifications, and Flare-Up Management

Following an oral biopsy, post-operative discomfort is usually mild and easily managed with paracetamol or ibuprofen; strong opioids are rarely necessary. Mild localised swelling and slight oozing of blood during the first 24 hours are normal physiological responses. Patients should avoid vigorous rinsing, spitting, or consuming hot beverages on the day of the procedure to protect the initial blood clot. Routine healing of the intraoral surgical site typically occurs within 10 to 14 days, aided by the rich vascular supply of the oral cavity.

Long-term day-to-day management requires deliberate dietary and oral hygiene adaptations to minimise mechanical and chemical trauma to fragile tissues. Patients should consume a soft, bland, and nutrient-dense diet during active flare-ups. It is advisable to avoid acidic fruits, vinegar, strong spices, chillies, rough crusts, and alcohol-containing mouthwashes. Switching to a non-foaming, SLS-free, mild-flavoured toothpaste and using an ultra-soft manual toothbrush helps prevent mechanical sloughing of the gums while maintaining plaque control.

When an unexpected flare-up develops, patients should follow a pre-arranged action plan developed with their oral specialist. This typically involves resuming high-potency topical corticosteroid applications at the earliest sign of mucosal erythema or discomfort, rather than waiting for deep erosions to establish. If white, removable curd-like plaques or an angular cracking at the corners of the lips appear alongside altered taste, patients should be evaluated for secondary candidiasis rather than escalating steroid doses.

Potential Complications, Malignant Transformation, and Red Flags

The most critical long-term concern in oral lichen planus management is its status as an oral potentially malignant disorder (OPMD). Extensive epidemiological reviews and consensus statements from the World Health Organization confirm that oral lichen planus carries a small but definitive risk of malignant transformation into oral squamous cell carcinoma, generally estimated in the medical literature at approximately 1% to 2% over extended follow-up periods. The risk is notably higher in long-standing erosive, ulcerative, and plaque-like subtypes, as well as in patients with persistent chronic inflammation.

Co-existing lifestyle risk factors significantly compound this baseline oncogenic risk. The consumption of tobacco products (cigarettes, cigars, bidi), alcohol, and particularly areca nut/betel quid formulations (paan, gutka, mawa) causes synergistic DNA damage to already inflamed, rapidly turning-over epithelial cells. Furthermore, longstanding gingival involvement can cause significant periodontal tissue destruction and recession, as painful desquamative lesions prevent adequate mechanical plaque removal, leading to secondary chronic periodontitis and potential tooth loss.

Patients must be educated on specific red flag signs that demand immediate, urgent re-evaluation by an oral and maxillofacial specialist. These include: a solitary non-healing ulcer that persists for more than two to three weeks despite active topical treatment; a discrete, hard or indurated lump within the cheek, tongue, or floor of the mouth; progressive, unexplained mucosal thickening or verrucous (wart-like) surface changes; spontaneous bleeding from a distinct focal lesion; regional lymph node enlargement in the neck; or developing numbness (paresthesia) in the lips, tongue, or jaw.

Evidence and further reading

Clinical management of oral lichen planus is guided by international consensus statements, clinical guidelines, and high-quality systematic reviews. Key reference frameworks are published by the World Health Organization Collaborating Centre for Oral Cancer and Precancer, the European Federation of Periodontology, the American Dental Association, and the British Association of Dermatologists. The Cochrane Collaboration has published extensive systematic reviews assessing the efficacy and safety of topical interventions and systemic immunomodulators for symptomatic oral lichen planus, consistently highlighting topical corticosteroids as the primary evidence-supported treatment.

Peer-reviewed dental and medical literature—including studies published in the *Journal of Oral Pathology & Medicine*, *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology*, the *International Journal of Oral and Maxillofacial Surgery*, and the *British Journal of Dermatology*—consistently emphasises the necessity of long-term clinical surveillance for all affected patients. Clinicians and researchers universally stress that maintaining lifelong 6-to-12-month review appointments is essential for detecting dysplastic changes at an early, curable stage and maintaining sustained symptomatic control.